Tiny Semaglutide Implant Could Sustain Weight Loss Long-Term
Vivani Medical is developing a GLP-1 implant using semaglutide to help patients maintain obesity drug benefits without repeated injections.
A California-based medical device company is betting that a miniature implant could solve one of the biggest challenges in obesity medicine: keeping patients on their medication long enough to sustain meaningful weight loss. Vivani Medical is developing a subcutaneous implant loaded with semaglutide, the same active compound found in Novo Nordisk's blockbuster obesity injection Wegovy and its diabetes counterpart Ozempic.
The move signals a growing push in the pharmaceutical and medtech industries to find delivery alternatives to weekly self-injections, which can lead to patient dropout and inconsistent dosing. A long-acting implant, by design, would remove the burden of remembering injections and could help smooth out the compliance gaps that undercut real-world results with GLP-1 drugs.
Read more Apple Sues OpenAI Over Alleged Trade Secret Theft by Ex-Staff →
Semaglutide has emerged as one of the most commercially significant molecules in modern medicine, propelling Novo Nordisk to become one of Europe's most valuable companies. Finding new delivery mechanisms for the drug represents both a scientific frontier and a substantial market opportunity, as millions of patients worldwide seek durable solutions to obesity and type 2 diabetes.
While the implant remains in development and has not yet reached late-stage clinical trials, Vivani's approach reflects a broader industry trend: moving beyond the pill-and-injection model toward devices that integrate directly into the body to manage chronic metabolic conditions. If successful, such technology could reshape how physicians approach long-term obesity treatment and patient adherence.
Continue reading at US Top News and Analysis.
